SCHEMBL954265

SCHEMBL954265

Cc1nc2ccc(-c3ccccc3)cn2c1-c1nc(-c2ccccc2)c(C(N)=O)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.51
DBF4 Q9UBU7 5/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
EPHB3 P54753 1/20 0.43
TGFBR1 P36897 3/20 0.41
SLC2A2 P11168 1/20 0.41
AKT1 P31749 3/20 0.40
AKT2 P31751 3/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
SLC2A1 P11166 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953255 0.91 CDC7 (0.49) CDC7DBF4CCNE1CDK2NPC1
SCHEMBL952124 0.87 CDK2 (0.53) CDC7DBF4CCNE1CDK2MAPT
Hydrochloric Acid SCHEMBL953025 0.86 CDK2 (0.52) CDC7DBF4CCNE1CDK2MAPT
SCHEMBL952128 0.85 CDC7 (0.58) CDC7DBF4NPC1RAB9ASLC2A2
SCHEMBL954263 0.83 BTK (0.44) CDC7DBF4CCNE1CDK2MAPT
SCHEMBL955310 0.79 CDC7 (0.52) CDC7DBF4CCNE1CDK2MAPT
SCHEMBL3780759 0.79 CDC7 (0.49) CDC7DBF4CCNE1CDK2MAPT
SCHEMBL957444 0.78 CDC7 (0.54) CDC7DBF4CCNE1CDK2MAPT
Hydrochloric Acid SCHEMBL953590 0.78 CDC7 (0.48) CDC7DBF4CCNE1CDK2MAPT
SCHEMBL952456 0.77 CDC7 (0.51) CDC7DBF4CCNE1CDK2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885CCNE1 1329/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885CCNE1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.